Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Neos Therapeutics Inc    NEOS

NEOS THERAPEUTICS INC (NEOS)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Neos Therapeutics : Xeris Pharmaceuticals, Inc. Appoints John P. Schmid to Board of Directors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/12/2017 | 02:16pm CEST

Release date- 11092017 - Chicago, IL and Austin, TX - Xeris Pharmaceuticals, Inc., a specialty biopharmaceutical company developing improved and differentiated injectable therapeutics for multiple indications including diabetes, announced the appointment of John P. Schmid to the Company's Board of Directors.

'We are delighted to welcome John to the Xeris Board,' said Paul Edick, President& CEO. 'John is an accomplished executive with an impressive track record in the healthcare and biotech industry. He brings a wealth of experience and knowledge that comes from building successful life science businesses including taking two companies public and generating significant shareholder value. John will play a key role as Xeris continues executing our vision to develop and commercialize our novel XeriSol and XeriJect formulation technologies.'

About John P. Schmid

John Schmid has over 30 years of experience in financial and executive management in the biotech industry and has raised over $900 million in private and public equity and debt financings. He is currently an independent Board Member and Audit Chair for Neos Therapeutics (Nasdaq: NEOS) and AnaptysBio (Nasdaq: ANAB). Mr. Schmid also serves on the Boards of Forge Therapeutics, Patara Pharma, and Speak, Inc. Previously, he was the Chief Financial Officer of Auspex Pharmaceuticals which he joined in 2013 and took public in early 2014 before it was sold to Teva in 2015 for $3.5 billion. Prior to Auspex, Mr. Schmid co-founded Trius Therapeutics in 2004 where he served as CFO through its IPO and until its sale to Cubist Pharmaceuticals in 2013 for over $700 million. Mr. Schmid received a BA in Economics from Wesleyan University and an MBA from the University of San Diego.

About Xeris Pharmaceuticals, Inc

Xeris is a Chicago, IL and Austin, TX-based, specialty biopharmaceutical company developing improved and differentiated injectable therapeutics for multiple indications including diabetes. The Company's proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intradermal delivery of highly concentrated, non-aqueous, ready-to-inject formulations of peptides, proteins, antibodies and small molecules using auto-injectors, multi-dose pens and pumps. Xeris' proprietary formulation platforms have the potential to offer distinct advantages over existing products and formulations including: up to 1000-fold lower injection volumes, long term room-temperature stability, elimination of reconstitution and refrigeration. All of these attributes can lead to products that are easier to use by patients, caregivers, health practitioners, and can reduce costs for payers and the healthcare system.

Contact:

Steve Pieper

Tel: 312-517-1384

Email: [email protected]

Web: www.xerispharma.com

(c) 2017 Electronic News Publishing -, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
ANAPTYSBIO INC -5.77% 77.9 Delayed Quote.-22.66%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NEOS THERAPEUTICS INC
05/15Neos Therapeutics to Present at the UBS Global Healthcare Conference
GL
05/15NEOS THERAPEUTICS : Reports First Quarter 2018 Financial Results
AQ
05/10NEOS THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
05/09NEOS THERAPEUTICS : 1Q Earnings Snapshot
AQ
05/09NEOS THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financi..
AQ
05/09Neos Therapeutics Reports First Quarter 2018 Financial Results
GL
05/07NEOS THERAPEUTICS : to Host First Quarter 2018 Financial Results Conference Call..
AQ
05/02NEOS THERAPEUTICS : to Host First Quarter 2018 Financial Results Conference Call..
AQ
04/30NEOS THERAPEUTICS,INC. (NASDAQ : NEOS) Files An 8-K Departure of Directors or Ce..
AQ
04/27NEOS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
News from SeekingAlpha
05/23Neos Therapeutics (NEOS) Presents At 2018 UBS Global Healthcare Conference - .. 
05/09Neos Therapeutics' (NEOS) CEO Vipin Garg on Q1 2018 Results - Earnings Call T.. 
05/09Neos Therapeutics misses by $0.03, beats on revenue 
05/03How To Play 'Am I Diversified?' In The Pharma/Biotech Space 
03/19Biotech Forum Daily Digest For March 19th 
Financials ($)
Sales 2018 56,8 M
EBIT 2018 -36,6 M
Net income 2018 -45,1 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 3,52x
Capi. / Sales 2019 1,80x
Capitalization 200 M
Chart NEOS THERAPEUTICS INC
Duration : Period :
Neos Therapeutics Inc Technical Analysis Chart | NEOS | US64052L1061 | 4-Traders
Technical analysis trends NEOS THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 16,8 $
Spread / Average Target 144%
EPS Revisions
Managers
NameTitle
Vipin K. Garg President, Chief Executive Officer & Director
Alan L. Heller Chairman
Margaret Cabano Vice President-Operations
Richard I. Eisenstadt CFO & Principal Accounting Officer
Bryant E. Fong Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
NEOS THERAPEUTICS INC-32.35%200
JOHNSON & JOHNSON-11.45%325 801
PFIZER-0.91%208 713
NOVARTIS-8.30%194 397
ROCHE HOLDING LTD.-9.17%189 708
MERCK AND COMPANY5.01%158 970